| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Improved Vaccine May Help Fight AIDS Throughout The World ALEXANDRIA, VA. -- July 10, 1997 -- An AIDS vaccine currently used in the United States and Europe has been improved with the aim of preventing HIV infection throughout the world. CEL-SCI Corporation’s original vaccine, called HGP-30, has been modified with the aim of providing better worldwide protection against a large number of HIV subtypes, and is called HGP-30W, where W stands for worldwide. Even though HIV infection is a major problem in the U.S. and Europe, the developing world has an even greater need for a protective AIDS vaccine. Due to the rapid mutation of the AIDS virus, virtually all AIDS vaccine candidates in human testing in the U.S., if successful, would be primarily useful only against U.S. and European HIV subtypes, but much less so against Asian and African HIV subtypes. By focusing on a part of the HIV virus that has fewer mutations, the researchers at CEL-SCI attempted to develop vaccine with broad application, or "one AIDS vaccine for worldwide use", because HGP-30W stimulates the immune system to recognize different HIV subtypes. Geert Kersten, Chief Executive Officer of CEL-SCI Corporation says: "The urgent need of the African and Asian countries for a preventive AIDS vaccine has long been disregarded by the pharmaceutical industry. We hope to be able to address their needs while, at the same time, developing an AIDS vaccine for use in the U.S. and Europe." HGP-30 has been shown to be safe and immunogenic in over 60 volunteers. At the 1996 International AIDS Conference it was reported by Dr. Kahn of San Francisco General Hospital that the vaccine also has conferred significant protection against a high level of HIV challenge dose in the SCID mouse model. More information on: CEL-SCI Corporation, HGP-30
|